Erlotinib
- Generic Name
- Erlotinib
- Brand Names
- Tarceva
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23N3O4
- CAS Number
- 183321-74-6
- Unique Ingredient Identifier
- J4T82NDH7E
- Background
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion...
- Indication
Erlotinib is indicated for:
The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.
- Associated Conditions
- Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer
- Associated Therapies
- -
Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2016-12-15
- Lead Sponsor
- Seattle Children's Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT02015728
- Locations
- 🇺🇸
Seattle Children's, Seattle, Washington, United States
A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT02013219
- Locations
- 🇺🇸
Yale University School Of Medicine, New Haven, Connecticut, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇭🇰The Chinese University of Hong Kong, Shatin, Hong Kong
Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation
- Conditions
- Interventions
- First Posted Date
- 2013-12-05
- Last Posted Date
- 2013-12-05
- Lead Sponsor
- Xinjiang Medical University
- Target Recruit Count
- 60
- Registration Number
- NCT02001896
- Locations
- 🇨🇳
Xinjiang medical university, Urumqi, Xinjiang, China
Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population
- Conditions
- Interventions
- First Posted Date
- 2013-12-04
- Last Posted Date
- 2016-01-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 45
- Registration Number
- NCT02000531
Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-11-28
- Last Posted Date
- 2018-04-02
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 14
- Registration Number
- NCT01998126
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 33
- Registration Number
- NCT01990261
Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer
- First Posted Date
- 2013-10-22
- Last Posted Date
- 2018-11-13
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 53
- Registration Number
- NCT01967095
- Locations
- 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States
A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors
- Conditions
- Interventions
- First Posted Date
- 2013-10-14
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Theodore Laetsch
- Target Recruit Count
- 4
- Registration Number
- NCT01962896
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸UT Southwestern Medical Center/Children's Medical Center, Dallas, Texas, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Study of Chemotherapy with Cisplatin/Carboplatin, and Docetaxel with or Without Erlotinib in Patients with Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection
- Conditions
- Interventions
- First Posted Date
- 2013-08-23
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 105
- Registration Number
- NCT01927744
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants
- Conditions
- Interventions
- First Posted Date
- 2013-07-16
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 111
- Registration Number
- NCT01900652
- Locations
- 🇺🇸
UCLA, Santa Monica, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸University of Iowa Hospital, Iowa City, Iowa, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.